ClearScript experts Nicole Christian, PharmD, Vice President of Clinical Account Services, and Mackenzie Pfeiffer, Director of Account Management, and Vice President of Sale, Kyle D. Johnson, will share an inside look at the latest PBM challenges, including recent negative press, the rebate debate (including the role of international sourcing), the GLP-1 controversy, and the rise of biosimilars.
suzetrigine (VX-548) Manufacturer: Vertex Approval Date: 1/30/2025 Suzetrigine possesses a novel mechanism of action as a voltage-gated sodium channel inactivator…
This year marks a significant milestone for ClearScript: 20 years of trusted stewardship in pharmacy benefits. For two decades, we…
In today’s fast-paced healthcare environment, prescribing medications can be challenging for both prescribers and patients. Determining drug coverage, understanding formulary…
At ClearScript, we’re committed to simplifying prescription drug benefits with user-friendly digital tools and resources to help members stay informed and engaged with their healthcare.
Neffy® (epinephrine nasal spray) was approved on August 9, 2024, for the emergency treatment of allergic reactions (type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients weighing at least 66 pounds.
For years, Humira® (adalimumab) has been a significant driver of healthcare costs due to its high price and utilization. With the introduction of several Humira biosimilars, learn how ClearScript has been monitoring the landscape and adapting strategies to provide members access to cost-effective therapy options for better health.
Why are the Big Three the most significant cost drivers in pharmacy benefits today? Because they put profits before patients. Fortunately, ClearScript is different. Listen to this coffee chat to learn how you can ensure your PBM is putting your members before profits.
Listen to learn why Tribal Nations are especially at risk when working with big PBMs that don’t keep their best interests at heart.
To help plans manage the rising cost of diabetes and weight management while improving member health, ClearScript offers our MedEmpower Fuel™ program.
On June 24, 2024, drug manufacturer Teva Pharmaceuticals announced the launch of an authorized generic formulation of Novo Nordisk’s Victoza (liraglutide). This marks the first generic glucagon-like peptide-1 (GLP-1) agonist available in the U.S. market.
ClearScript was an early pioneer of transparency in pharmacy benefit management. Unlike the Big Three PBMs, we put patients before profits.